During ECCO 2024, held from February 21st to 24th, international IBD specialists came to Stockholm to present the latest news in IBD care. In this setting, our colleagues Oliver Dähn and Christian Reinhard had the privilege of presenting the following two posters:
Poster 1:
P437 – Feasibility study of a Point-of-Care assay for rapid determination of anti-TNFα biologics in capillary blood
Poster 2:
P473 – Comparison of clinical performance of fecal calprotectin of laboratory methods with lateral flow based POC and home tests
The BÜHLMANN IBD portfolio aims to improve patient’s quality of life with Rapid diagnosis and treatment through rapid tests for therapeutic drug monitoring using the Quantum Blue® Reader and for fecal calprotectin, which can be conducted in the laboratory, doctor’s office, or even at home with IBDoc®.
Social Links